Can Valganciclovir be paid for by medical insurance? Medical insurance reimbursement policy analysis

Although Valganciclovir (valganciclovir) has been officially launched in China, it has not been included in the national medical insurance catalog so far, which means that patients usually need to bear the entire cost of the drug when using it. According to the latest market price, 0.45Vasavi60 tablets are priced at about 14,000 to 5,000 yuan, which is relatively expensive. Due to the lack of medical insurance reimbursement support, patients may face greater financial pressure, especially those who require long-term medication.

The inclusion in medical insurance reimbursement policies usually requires strict approval and evaluation, taking into account multiple aspects such as the drug's efficacy, safety, cost-effectiveness, and clinical needs. Although Vancevir plays an important role as an antiviral drug, especially in the treatment of cytomegalovirus infections, its high market price and the existence of alternative drugs may be one of the reasons why it has not been included in the medical insurance catalog. In the future, with the accumulation of more clinical data and policy adjustments, the possibility of Vancevi being included in medical insurance still exists.

From the international market, there are large differences in the price of Vancevi. In overseas markets, the price range of original drugs such as the Swiss imported version, Indian version and Turkish version ranges from more than 4,000 to 15,000 yuan, and the prices are slightly advantageous compared to domestic ones. At the same time, the price of the generic version produced by Laos Lucius is more affordable, about more than 1,000 yuan, and the drug ingredients are basically the same as the original drug, providing patients with a more economical choice. If patients cannot afford the high-priced original drugs, they can consider purchasing generic drugs through formal channels, but they must ensure drug quality and legal compliance.

To sum up, Vancevi is currently not included in the scope of medical insurance payment in China. Patients need to bear the cost of the drug themselves, and the price is relatively high. Adjustments to medical insurance policies take time, and patients should pay attention to the latest developments. At the same time, you can weigh and choose the appropriate drug version and purchase channel based on your own financial situation and disease needs. Only by using drugs rationally and conducting treatment under the guidance of a doctor can the efficacy and safety be guaranteed to the greatest extent.

Reference materials:https://go.drugbank.com/drugs/DB01610